Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Apr 1.

Published in final edited form as: Exp Hematol. 2014 Jan 6;42(4):282–293.e4. doi: 10.1016/j.exphem.2013.12.007

(A) EOL-1 cells were incubated in control medium in the absence (Co) or presence of ponatinib, sorafenib, masitinib, sunitinib or erlotinib (each 0.01, 0.1 or 1 μM) at 37°C for 4 hours. After incubation, cells were analyzed for expression of pAKT, pS6, and pSTAT5, by flow cytometry as described in the text. Results are expressed as percent of control and represent the mean±SD from at least 3 independent experiments. DMSO (solvent) per se did not show any effect on phosphorylation of tested molecules (not shown). Asterisk, p<0.05. (B) EOL-1 cells were incubated in control medium in the absence (Control) or presence of ponatinib, sunitinib, sorafenib, masitinib or erlotinib (each 0.1 or 1 μM) at 37°C for 4 hours. After incubation, cells were analyzed for expression of pPDGFR, pS6 and pSTAT5 by western blotting as described in the text. (C) EOL-1 cells were incubated in control medium (Co) or in various concentrations of everolimus, BEZ235, pimozide, or piceatannol at 37°C for 48 hours. After incubation, ³H-thymidine uptake was measured. Results are expressed as percent of control and represent the mean±SD from 3 independent experiments. Asterisk: p<0.05.

(A) EOL-1 cells were incubated in control medium in the absence (Co) or presence of ponatinib, sorafenib, masitinib, sunitinib or erlotinib (each 0.01, 0.1 or 1 μM) at 37°C for 4 hours. After incubation, cells were analyzed for expression of pAKT, pS6, and pSTAT5, by flow cytometry as described in the text. Results are expressed as percent of control and represent the mean±SD from at least 3 independent experiments. DMSO (solvent) per se did not show any effect on phosphorylation of tested molecules (not shown). Asterisk, p<0.05. (B) EOL-1 cells were incubated in control medium in the absence (Control) or presence of ponatinib, sunitinib, sorafenib, masitinib or erlotinib (each 0.1 or 1 μM) at 37°C for 4 hours. After incubation, cells were analyzed for expression of pPDGFR, pS6 and pSTAT5 by western blotting as described in the text. (C) EOL-1 cells were incubated in control medium (Co) or in various concentrations of everolimus, BEZ235, pimozide, or piceatannol at 37°C for 48 hours. After incubation, ³H-thymidine uptake was measured. Results are expressed as percent of control and represent the mean±SD from 3 independent experiments. Asterisk: p<0.05.